Monoclonal antibodies are the most important new experimental treatment for migraine. They target the calcitonin gene-related peptide (CGRP). When a migraine patient is having an attack, this compound is increased in the blood and not so between attacks. Injecting this compound into a migraine patient always triggers an attack.

There are 3 monoclonal antibodies to CGRP being tested. Preliminary results seem positive and side effects very low. Our center is currently recruiting for a trial of the compound termed LY2951742. This is a phase II trial, but there are already plans for a phase III trial with the hope of obtaining FDA indication and making this medication available to all migraine patients.

Contact our center for further information about the trial.

Visit our Facebook page and give us your support!

Read More